N
Nicholas Mitsiades
Researcher at Baylor College of Medicine
Publications - 187
Citations - 22163
Nicholas Mitsiades is an academic researcher from Baylor College of Medicine. The author has contributed to research in topics: Bortezomib & Apoptosis. The author has an hindex of 68, co-authored 175 publications receiving 20925 citations. Previous affiliations of Nicholas Mitsiades include Harvard University & Lovelace Respiratory Research Institute.
Papers
More filters
Journal ArticleDOI
Integrative genomic profiling of human prostate cancer
Barry S. Taylor,Nikolaus Schultz,Haley Hieronymus,Anuradha Gopalan,Yonghong Xiao,Brett S. Carver,Vivek K. Arora,Poorvi Kaushik,Ethan Cerami,Boris Reva,Yevgeniy Antipin,Nicholas Mitsiades,Thomas Landers,Igor Dolgalev,John E. Major,Manda Wilson,Nicholas D. Socci,Alex E. Lash,Adriana Heguy,James A. Eastham,Howard I. Scher,Victor E. Reuter,Peter T. Scardino,Chris Sander,Charles L. Sawyers,Charles L. Sawyers,William L. Gerald +26 more
TL;DR: Analysis of genomic and clinical outcome data from 218 prostate cancer tumors revealed that copy-number alterations robustly define clusters of low- and high-risk disease beyond that achieved by Gleason score.
Journal ArticleDOI
NF-κB as a Therapeutic Target in Multiple Myeloma *
Teru Hideshima,Dharminder Chauhan,Paul G. Richardson,Constantine S. Mitsiades,Nicholas Mitsiades,Toshiaki Hayashi,Nikhil C. Munshi,Lenny Dang,Alfredo C. Castro,Vito Palombella,Julian Adams,Kenneth C. Anderson +11 more
TL;DR: These studies demonstrate that specific targeting of NF-κB can overcome the growth and survival advantage conferred both by tumor cell binding to BMSCs and cytokine secretion in the BM milieu.
Journal ArticleDOI
Molecular sequelae of proteasome inhibition in human multiple myeloma cells
Nicholas Mitsiades,Constantine S. Mitsiades,Vassiliki Poulaki,Dharminder Chauhan,Galinos Fanourakis,Xuesong Gu,Charles G. Bailey,Marie Joseph,Towia A. Libermann,Steven P. Treon,Nikhil C. Munshi,Paul G. Richardson,Teru Hideshima,Kenneth C. Anderson +13 more
TL;DR: The molecular sequelae of PS-341 treatment in MM cells are characterized and the rationale for future clinical trials of this promising agent, in combination with conventional and novel therapies, to improve patient outcome in MM is explained.
Journal ArticleDOI
The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications.
Nicholas Mitsiades,Constantine S. Mitsiades,Paul G. Richardson,Vassiliki Poulaki,Yu-Tzu Tai,Dharminder Chauhan,Galinos Fanourakis,Xuesong Gu,Charles G. Bailey,Marie Joseph,Towia A. Libermann,Robert L. Schlossman,Nikhil C. Munshi,Teru Hideshima,Kenneth C. Anderson +14 more
TL;DR: This study found that subtoxic concentrations of PS-341 potently sensitized MM cell lines and patient cells to DNA-damaging chemotherapeutic agents such as doxorubicin and melphalan, including cells resistant to these drugs and those isolated from a patient who had relapsed afterPS-341 monotherapy.
Journal ArticleDOI
Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications
Nicholas Mitsiades,Constantine S. Mitsiades,Vassiliki Poulaki,Dharminder Chauhan,Paul G. Richardson,Teru Hideshima,Nikhil C. Munshi,Steven P. Treon,Kenneth C. Anderson +8 more
TL;DR: The mechanism of action of IMiDs against MM cells in vitro is delineated and form the basis for clinical trials of these agents, alone and coupled with conventional and other novel therapies, to improve outcome in MM.